Suven targets Q2 2027 Masupirdine topline data release

Suven Life Sciences Limited expects potentially to report topline data from its global Phase 3 Masupirdine trial in Q2 of calendar year 2027, following completion of the enrolment milestone. Suven expects the last patient last visit in Q1 2027, enabling database lock before the potential data release for agitation in Alzheimer’s dementia.

When will Suven report Masupirdine topline data?

Suven expects potential reporting of Masupirdine topline data in Q2 of calendar year 2027. The stated timetable follows the expected last patient last visit in Q1 2027, after which the global Phase 3 trial can progress towards database lock. Suven disclosed the sequence in its 5 November 2026 release for the quarter and six months ended 30 September 2026.

The Q2 2027 timing is an expectation, not a confirmed reporting date. Suven said data could be reported “potentially” in that quarter and warned that forward-looking statements may differ from assumptions because of research and clinical-development outcomes, outsourcing trends, economic conditions and other factors. The disclosed process is complete enrolment, last patient last visit, database lock and then topline reporting.

Masupirdine, designated SUVN-502, is being evaluated for agitation in Alzheimer’s dementia. Suven described the trial as global and in Phase 3, but did not disclose efficacy findings, safety results, participant numbers, study endpoints or statistical outcomes as of 5 November 2026. The next operational milestone identified for the programme is the Q1 2027 final patient visit.

What changed in Suven’s Masupirdine Phase 3 trial?

Suven has completed the enrolment milestone in the global Phase 3 Masupirdine trial. The 30 September 2026 results release therefore shifts the disclosed focus from participant recruitment to follow-up through the expected Q1 2027 last patient last visit. No previous enrolment target or recruitment total was included in the announcement.

The filing does not report an interim Masupirdine clinical readout. It also does not state whether the trial has met any efficacy or safety measure, so the completed enrolment milestone is a procedural development rather than a disclosed trial outcome. The potential Q2 2027 topline report is the next data-related event Suven specified.

Masupirdine’s status differs from Suven’s Ropanicant programme, designated SUVN-911. Suven said Ropanicant completed a Phase 2B study in the United States with a successful outcome, whereas it provided no comparable outcome statement for Masupirdine’s continuing Phase 3 study. Ropanicant is targeted for a global Phase 3 programme start in Q2 2027, the same quarter as Masupirdine’s potential topline data.

Which other Suven CNS programmes have milestones?

Suven reported updates on four other central nervous system, or CNS, candidates alongside Masupirdine. Samelisant, designated SUVN-G3031, remains in a global Phase 3 clinical study intended to confirm efficacy and safety in narcolepsy. Suven did not provide a completion date, recruitment figure or data-reporting timetable for Samelisant in the 5 November 2026 release.

Ropanicant completed its US Phase 2B clinical study with what Suven called a successful outcome. Management is targeting initiation of a global Phase 3 programme during Q2 of calendar year 2027. This is a planned trial start, rather than a data release, and Suven did not disclose the Phase 2B patient count, endpoints or numerical results.

Usmarapride, designated SUVN-D4010, entered a Phase 2 proof-of-concept study for cognitive dysfunction during October 2026. That places Usmarapride earlier in development than Masupirdine and Samelisant, both of which are in Phase 3. Suven did not state a recruitment target, study completion date or expected result date for the October 2026 study.

SUVN-I6107 completed its Phase 1 study for safety and pharmacokinetics, which concerns how a drug is processed by the body. Suven said Phase 2-enabling toxicological studies were under way on 5 November 2026. Unlike Ropanicant, Suven did not give a calendar-quarter target for initiating Phase 2 work for SUVN-I6107.

How did Suven’s September 2026 quarter compare financially?

Suven reported consolidated revenue of Rs 7.933 crore for the quarter ended 30 September 2026, up from Rs 4.697 crore in the quarter ended 30 September 2025 but down from Rs 11.089 crore in the preceding quarter ended 30 June 2026. Research and development, or R&D, and operational expenses were Rs 112.115 crore, compared with Rs 80.690 crore a year earlier and Rs 136.068 crore in the June 2026 quarter.

Suven’s consolidated loss after tax was Rs 106.942 crore for the September 2026 quarter, against a loss of Rs 77.310 crore a year earlier and Rs 127.610 crore in the June 2026 quarter. Total expenses of Rs 114.875 crore exceeded revenue of Rs 7.933 crore; depreciation and amortisation was Rs 2.302 crore, while finance cost was Rs 45.8 lakh.

For the six months ended 30 September 2026, revenue was Rs 19.022 crore, compared with Rs 7.164 crore in the corresponding six months of 2025. R&D and operational expenses rose to Rs 248.183 crore from Rs 133.305 crore, while loss after tax increased to Rs 234.552 crore from Rs 128.827 crore. Suven describes its business as drug discovery and development of new chemical entities for CNS disorders.

Conclusion

Suven’s 5 November 2026 update gives Masupirdine a defined next sequence: enrolment is complete, last patient last visit is expected in Q1 2027 and topline data may follow in Q2 2027. Its other disclosed programmes span Samelisant’s continuing Phase 3 narcolepsy study, Ropanicant’s planned Phase 3 start, Usmarapride’s October 2026 Phase 2 proof-of-concept initiation and SUVN-I6107’s Phase 2-enabling toxicology work.

The next disclosed events to watch are Masupirdine’s expected Q1 2027 last patient last visit and potential Q2 2027 topline report, alongside management’s Q2 2027 target to begin Ropanicant’s global Phase 3 programme. Suven has not disclosed Masupirdine participant numbers or trial outcomes, nor scheduled completion dates for Samelisant, Usmarapride or SUVN-I6107.